Downregulation of DIP2B as a prognostic marker inhibited cancer proliferation and migration and was associated with immune infiltration in lung adenocarcinoma via CCND1 and MMP2

• Published in: Heliyon 2024-06, Vol.10 (12), p.e32025, Article e32025
• Main Authors: Wu, Chuang-Yan, Liu, Zhao, Luo, Wei-Min, Huang, Huan, Jiang, Ni, Du, Zhi-Peng, Wang, Fang-Ming, Han, Xu, Ye, Guan-Chao, Guo, Qiang, Chen, Jiu-Ling
• Format: Article
• Language: English
• Subjects: adenocarcinoma; bioinformatics; Biomarker; biomarkers; cell division; cell proliferation; DIP2B; DNA repair; Immune microenvironment; Lung adenocarcinoma; lungs; neoplasm cells; neoplasm progression; nomogram; Prognosis; protein synthesis; risk factors; tumor suppressor proteins
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e32025

DIP2B is related to cancer progression. This study investigated the roles and pathways of DIP2B in lung adenocarcinoma (LUAD). DIP2B expression and the relationship between survival time of cancer patients and DIP2B expression were analyzed. The relationship between DIP2B expression and survival time in LUAD patients was evaluated by a meta-analysis. Cox and survival analyses were used to evaluate the prognostic factors and construct a prognostic nomogram. The mechanisms and effects of DIP2B and the relationship between DIP2B expression and the immune microenvironment were investigated using bioinformatics, CCK-8, western blotting, and transwell experiments. DIP2B was overexpressed in LUAD tissues. DIP2B overexpression was associated with shorter prognosis and was an unfavorable risk factor for prognosis in LUAD patients. DIP2B co-expressed genes were involved in cell division, DNA repair, cell cycle, and others. Inhibition of DIP2B expression could downregulate the proliferation, migration, and invasion of LUAD A549 and H1299 cells, which was related to the decrease in CCND1 and MMP2 protein expression. BRCA1 overexpression was associated with short prognosis, and the nomogram formed by DIP2B and BRCA1 was associated with a poor prognosis in LUAD patients. DIP2B expression correlated with immune cells (such as CD8 T cells, Tcm, and iDCs) and cell markers. DIP2B is a potential biomarker of poor prognosis and the immune microenvironment in LUAD. Inhibition of DIP2B expression downregulated cancer cell proliferation, migration, and invasion, which might be related to the decrease in CCND1 and MMP2 protein expression. DIP2B-related nomograms might be useful tools for predicting the prognosis of LUAD patients.